Ariana M. Familiar

Ariana M. Familiar

Auto-generated profile, based on publicly available information

Ariana M. Familiar

Center for Data-Driven Discovery in Biomedicine (D3b), Children’s Hospital of Philadelphia, Philadelphia, Pa

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
AVArastoo Vossough
Arastoo Vossough
NKNastaran Khalili
Nastaran Khalili
AFAriana M. Familiar
Ariana M. Familiar
DGDeep Gandhi
Deep Gandhi
KVKarthik Viswanathan
Karthik Viswanathan
AKAnahita Fathi Kazerooni
Anahita Fathi Kazerooni
BACKGROUND AND PURPOSE: Tumor segmentation is essential in surgical and treatment planning and response assessment and monitoring in pediatric brain tumors, the leading cause of cancer-related death among children. However, manual segmentation is time-consuming and has high interoperator variability, underscoring the need for more efficient methods. After training, we compared 2 deep-learning-based 3D segmentation models, DeepMedic and nnU-Net, with pediatric-specific multi-institutional brain tumor data based on multiparametric MR images. MATERIALS AND METHODS: Multiparametric preoperative MR imaging scans of 339 pediatric patients (n = 293 internal and n = 46 external cohorts) with a variety of tumor subtypes were preprocessed and manually segmented into 4 tumor subregions, ie, enhancing tumor, nonenhancing tumor, cystic components, and peritumoral edema. After training, performances of the 2 models on internal and external test sets were evaluated with reference to ground truth manual segmentations. Additionally, concordance was assessed by comparing the volume of the subregions as a percentage of the whole tumor between model predictions and ground truth segmentations using the Pearson or Spearman correlation coefficients and the Bland-Altman method. RESULTS: The mean Dice score for nnU-Net internal test set was 0.9 (SD, 0.07) (median, 0.94) for whole tumor; 0.77 (SD, 0.29) for enhancing tumor; 0.66 (SD, 0.32) for nonenhancing tumor; 0.71 (SD, 0.33) for cystic components, and 0.71 (SD, 0.40) for peritumoral edema, respectively. For DeepMedic, the mean Dice scores were 0.82 (SD, 0.16) for whole tumor; 0.66 (SD, 0.32) for enhancing tumor; 0.48 (SD, 0.27) for nonenhancing tumor; 0.48 (SD, 0.36) for cystic components, and 0.19 (SD, 0.33) for peritumoral edema, respectively. Dice scores were significantly higher for nnU-Net (P ≤ .01). Correlation coefficients for tumor subregion percentage volumes were higher (0.98 versus 0.91 for enhancing tumor, 0.97 versus 0.75 for nonenhancing tumor, 0.98 versus 0.80 for cystic components, 0.95 versus 0.33 for peritumoral edema in the internal test set). Bland-Altman plots were better for nnU-Net compared with DeepMedic. External validation of the trained nnU-Net model on the multi-institutional Brain Tumor Segmentation Challenge in Pediatrics (BraTS-PEDs) 2023 data set revealed high generalization capability in the segmentation of whole tumor, tumor core (a combination of enhancing tumor, nonenhancing tumor, and cystic components), and enhancing tumor with mean Dice scores of 0.87 (SD, 0.13) (median, 0.91), 0.83 (SD, 0.18) (median, 0.89), and 0.48 (SD, 0.38) (median, 0.58), respectively. CONCLUSIONS: The pediatric-specific data-trained nnU-Net model is superior to DeepMedic for whole tumor and subregion segmentation of pediatric brain tumors.

1 May 2024 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
DTDivyanshu Tak
Divyanshu Tak
ZYZezhong Ye
Zezhong Ye
AZAnna Zapaischykova
Anna Zapaischykova
YZYining Zha
Yining Zha
ABAidan Boyd
Aidan Boyd
BKBenjamin H. Kann
Benjamin H. Kann
"Just Accepted" papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence. This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content. Purpose To develop and externally test a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pediatric low-grade glioma (pLGG). Materials and Methods This retrospective study included two pLGG datasets with linked genomic and diagnostic T2-weighted MRI data of patients: BCH (development dataset, n = 214 [60 (28%) BRAF-Fusion, 50 (23%) BRAF V600E, 104 (49%) wild-type), and the Children's Brain Tumor Network (external testing, n = 112 [60 (53%) with BRAF-Fusion, 17 (15%) BRAF-V600E, 35 (32%) wild-type]). A deep learning pipeline was developed to classify BRAF mutational status (V600E versus Fusion versus Wild-Type) via a two-stage process: 1) 3D tumor segmentation and extraction of axial tumor images, and 2) slice-wise, deep learning-based classification of mutational status. Knowledge-transfer and self-supervised approaches were investigated to prevent model overfitting, with a primary endpoint of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, we developed a novel metric, COMDist (Center of Mass Distance), that quantifies the model attention around the tumor. Results A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest classification performance with AUC of 0.82 [95% CI: 0.72-0.91], 0.87 [95% CI: 0.61-0.97], and 0.85[95% CI: 0.66-0.95] for Wild-Type, BRAF-Fusion and BRAF-V600E, respectively, on internal testing. On external testing, the pipeline yielded AUC of 0.72 [95% CI: 0.64-0.86], 0.78 [95% CI: 0.61-0.89], and 0.72 [95% CI: 0.64-0.88] for Wild-Type, BRAF-Fusion and BRAF-V600E classes, respectively. Conclusion Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pLGG mutational status prediction in a limited data scenario. ©RSNA, 2024.

23 December 2022 in Neoplasia
Verified
Journal Article
Open access
DHDebanjan Haldar
Debanjan Haldar
AKAnahita Fathi Kazerooni
Anahita Fathi Kazerooni
SASherjeel Arif
Sherjeel Arif
AFAriana Familiar
Ariana Familiar
RMRachel Madhogarhia
Rachel Madhogarhia
ANAli Nabavizadeh
Ali Nabavizadeh
Despite advancements in molecular and histopathologic characterization of pediatric low-grade gliomas (pLGGs), there remains significant phenotypic heterogeneity among tumors with similar categorizations. We hypothesized that an unsupervised machine learning approach based on radiomic features may reveal distinct pLGG imaging subtypes. Multi-parametric MR images (T1 pre- and post-contrast, T2, and T2 FLAIR) from 157 patients with pLGGs were collected and 881 quantitative radiomic features were extracted from tumorous region. Clustering was performed using K-means after applying principal component analysis (PCA) for feature dimensionality reduction. Molecular and demographic data was obtained from the PedCBioportal and compared between imaging subtypes. K-means identified three distinct imaging-based subtypes. Subtypes differed in mutational frequencies of BRAF (p < 0.05) as well as the gene expression of BRAF (p<0.05). It was also found that age (p < 0.05), tumor location (p < 0.01), and tumor histology (p < 0.0001) differed significantly between the imaging subtypes. In this exploratory work, it was found that clustering of pLGGs based on radiomic features identifies distinct, imaging-based subtypes that correlate with important molecular markers and demographic details. This finding supports the notion that incorporation of radiomic data could augment our ability to better characterize pLGGs.

21 May 2024 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
AFAriana M Familiar
Ariana M Familiar
AKAnahita Fathi Kazerooni
Anahita Fathi Kazerooni
AVArastoo Vossough
Arastoo Vossough
JWJeffrey B Ware
Jeffrey B Ware
SBSina Bagheri
Sina Bagheri
ANAli Nabavizadeh
Ali Nabavizadeh
MR imaging is central to the assessment of tumor burden and changes over time in neuro-oncology. Several response assessment guidelines have been set forth by the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groups in different tumor histologies; however, the visual delineation of tumor components using MRIs is not always straightforward, and complexities not currently addressed by these criteria can introduce inter- and intra-observer variability in manual assessments. Differentiation of non-enhancing tumors from peritumoral edema, mild enhancement from absence of enhancement, and various cystic components can be challenging; particularly given a lack of sufficient and uniform imaging protocols in clinical practice. Automated tumor segmentation with artificial intelligence (AI) may be able to provide more objective delineations, but rely on accurate and consistent training data created manually (ground truth). Herein, this paper reviews existing challenges and potential solutions to identifying and defining subregions of pediatric brain tumors (PBTs) that are not explicitly addressed by current guidelines. The goal is to assert the importance of defining and adopting criteria for addressing these challenges, as it will be critical to achieving standardized tumor measurements and reproducible response assessment in PBTs, ultimately leading to more precise outcome metrics and accurate comparisons among clinical studies.

9 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AZAnna Zapaishchykova
Anna Zapaishchykova
KLKevin X. Liu
Kevin X. Liu
ASAnurag Saraf
Anurag Saraf
ZYZezhong Ye
Zezhong Ye
PCPaul J. Catalano
Paul J. Catalano
BKBenjamin H. Kann
Benjamin H. Kann
Lean muscle mass (LMM) is an important aspect of human health. Temporalis muscle thickness is a promising LMM marker but has had limited utility due to its unknown normal growth trajectory and reference ranges and lack of standardized measurement. Here, we develop an automated deep learning pipeline to accurately measure temporalis muscle thickness (iTMT) from routine brain magnetic resonance imaging (MRI). We apply iTMT to 23,876 MRIs of healthy subjects, ages 4 through 35, and generate sex-specific iTMT normal growth charts with percentiles. We find that iTMT was associated with specific physiologic traits, including caloric intake, physical activity, sex hormone levels, and presence of malignancy. We validate iTMT across multiple demographic groups and in children with brain tumors and demonstrate feasibility for individualized longitudinal monitoring. The iTMT pipeline provides unprecedented insights into temporalis muscle growth during human development and enables the use of LMM tracking to inform clinical decision-making.

29 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NKNastaran Khalili
Nastaran Khalili
HSHossein Shooli
Hossein Shooli
NHNastaran Hosseini
Nastaran Hosseini
AKAnahita Fathi Kazerooni
Anahita Fathi Kazerooni
AFAriana Familiar
Ariana Familiar
ANAli Nabavizadeh
Ali Nabavizadeh
Clinical management in neuro-oncology has changed to an integrative approach that incorporates molecular profiles alongside histopathology and imaging findings. While the World Health Organization (WHO) guideline recommends the genotyping of informative alterations as a routine clinical practice for central nervous system (CNS) tumors, the acquisition of tumor tissue in the CNS is invasive and not always possible. Liquid biopsy is a non-invasive approach that provides the opportunity to capture the complex molecular heterogeneity of the whole tumor through the detection of circulating tumor biomarkers in body fluids, such as blood or cerebrospinal fluid (CSF). Despite all of the advantages, the low abundance of tumor-derived biomarkers, particularly in CNS tumors, as well as their short half-life has limited the application of liquid biopsy in clinical practice. Thus, it is crucial to identify the factors associated with the presence of these biomarkers and explore possible strategies that can increase the shedding of these tumoral components into biological fluids. In this review, we first describe the clinical applications of liquid biopsy in CNS tumors, including its roles in the early detection of recurrence and monitoring of treatment response. We then discuss the utilization of imaging in identifying the factors that affect the detection of circulating biomarkers as well as how image-guided interventions such as focused ultrasound can help enhance the presence of tumor biomarkers through blood–brain barrier (BBB) disruption.